Search - tctmd.com

Displaying 181 - 200 of 392

Sort: Relevancy | Date

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

L.A. McKeown

May 28, 2020

News Daily News

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Yael L. Maxwell

May 28, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Daily News

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Michael O'Riordan

April 08, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Daily News

Olive Oil Consumption Linked to CVD Benefits in the US

Shelley Wood

March 09, 2020

News Daily News

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Michael O'Riordan

March 06, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Yael L. Maxwell

January 16, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

Advertisement

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

US Poverty Drives CVD in Low-Income Adults Beyond Traditional Risk Factors

Women, Elderly, Minorities Vastly Underrepresented in Clinical Trials Over Decades

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Adherence to Healthy Habits Linked to Years Free of Chronic Disease

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Olive Oil Consumption Linked to CVD Benefits in the US

One Egg a Day? No Link to Risk of CVD, Mega-Meta-analysis Says

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Coconut Oil Ups LDL Cholesterol Compared With Other Fats: Meta-analysis

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content